Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henrik Biering

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Hormone Research|June 5, 2003
Manifestation of thyrotoxic periodic paralysis in two patients with adrenal adenomas and hyperandrogenaemiaHenrik Biering, Jürgen Bauditz, Matthias Pirlich, et al.
Biomedicines|March 6, 2021
The ElonginB/C-Cullin5-SOCS-Box-Complex Is a Potential Biomarker for Growth Hormone DisordersWilhelm Gossing, Lars Radke, Henrik Biering, et al.
The Journal of Clinical Endocrinology and Metabolism|March 13, 2002
Loss of body cell mass in Cushing's syndrome: effect of treatmentMatthias Pirlich, Henrik Biering, Helga Gerl, et al.
European Journal of Endocrinology|March 4, 2018
Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trialGudmundur Johannsson, Ulla Feldt-Rasmussen, Ida Holme Håkonsson, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Hormone Research|June 5, 2003
Manifestation of thyrotoxic periodic paralysis in two patients with adrenal adenomas and hyperandrogenaemiaHenrik Biering, Jürgen Bauditz, Matthias Pirlich, et al.
Biomedicines|March 6, 2021
The ElonginB/C-Cullin5-SOCS-Box-Complex Is a Potential Biomarker for Growth Hormone DisordersWilhelm Gossing, Lars Radke, Henrik Biering, et al.
The Journal of Clinical Endocrinology and Metabolism|March 13, 2002
Loss of body cell mass in Cushing's syndrome: effect of treatmentMatthias Pirlich, Henrik Biering, Helga Gerl, et al.
European Journal of Endocrinology|March 4, 2018
Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trialGudmundur Johannsson, Ulla Feldt-Rasmussen, Ida Holme Håkonsson, et al.
Pageof 1